Jefferies

Moderna Inc (NASDAQ: MRNA) initiated a large-scale Phase 3 study of its coronavirus vaccine candidate in mid-July. An analyst at Jefferies conducted a statistical analysis of the study design to arrive at the likely timing of the data readout — whether they think the study will achieve...

Immunomedics, Inc. (NASDAQ: IMMU) stock, which has been on a broader upward trajectory since FDA approved its lead asset Trodelvy, has further room to run, according to a Jefferies analyst.  The Immunomedics Analyst: Chris Howerton reiterated a Buy rating on Immunomedics and...

Microsoft Corporation (NASDAQ: MSFT) is poised to report strong fourth-earnings Wednesday, according to tech analysts. Wedbush’s Daniel Ives maintained an Outperform rating on Microsoft with a $260 price target, while Jefferies’ Brent Thill maintained a Buy rating and raised the...

Moderna Inc (NASDAQ: MRNA) shares are surging above the $70 level for the first time since late May following sell-side commentary on its coronavirus vaccine program. The Moderna Analyst: Jefferies analyst Michael Yee initiated coverage of Moderna with a Buy rating and $90 price target. The...

The Past Week, In A Nutshell What Happened: “It’s certainly been a wild ride for stocks in 2020,” noted researchers at LPL Financial. “Barely past the halfway point, the year has already brought the worst pandemic to hit the U.S. in over 100 years, an unprecedented...

Lululemon Athletica Inc (NASDAQ: LULU) shares gained 5.5% on Tuesday after the company announced a $500 million buyout of in-home fitness company Mirror. Mirror is Lululemon’s first major acquisition, and the deal is expected to close in the second half of the year. New Way To Connect Bank of...

Salesforce.com, inc. (NYSE: CRM) shares are up 21.7% in the past year. The cloud-based customer relationship management giant has been one of the best large-cap growth stocks in the market in recent years, and at least one large option trader is expecting more of the same from the stock over the...

Shares of care rental company Hertz Global Holdings Inc (NYSE: HTZ), which filed for Chapter 11 bankruptcy in late May, were advancing strongly Wednesday. What Happened: Speculation concerning a sale of Hertz gained ground after Jefferies analyst Hamzah Mazari said in a note that the ...

Netflix Inc (NASDAQ: NFLX) shares have held their own despite the turmoil of the COVID-19 pandemic, thanks to strong subscriber additions facilitated by the lockdowns in force globally.  Netflix Shares Peak, Pause  The streaming giant is among the best-performing S&P 500 stocks year-...

Apple Inc. (NASDAQ: AAPL) analysts are projecting that Cupertino will weather the coronavirus pandemic and emerge in good shape.  The Apple Analysts BofA Securities analyst Wamsi Mohan reiterated a Buy rating on Apple shares and lifted the price target from $320 to $340. Deutsche Bank...

Despite near-term volatility related to the coronavirus, Netflix Inc (NASDAQ: NFLX) is still winning buyers. The Netflix Rating Jefferies analysts Alex Giaimo and Brent Thill initiated coverage of Netflix with a Buy rating and a $520 price target. The Netflix Thesis Their bullish call is based on...

Jefferies analysts recently visited a Best Buy Co Inc (NYSE: BBY) store and left with a positive impression of the retail's in-store appointment process. Retail expert Kristin Bentz isn't as bullish on the future of shopping. Jefferies: 'A Treat' Jefferies analysts said in a May 6...

Macro trends are favorable for WW International Inc (NASDAQ: WW), and its digital shift is likely to boost margins and capital returns, according to Jefferies. The WW International Analyst Stephanie Wissink initiated coverage of WW International with a Buy rating and $32 price target. The WW...

Following in the footsteps of its bigger rival Alibaba Group Holding Ltd – ADR (NYSE: BABA), JD.Com Inc (NASDAQ: JD) is planning to test the IPO waters in Hong Kong very soon, if reports are to be believed. Alibaba undertook a secondary listing of its shares in the Hong Kong market late...

Keros Therapeutics Inc (NASDAQ: KROS), a clinical-stage biopharma focused on the development of treatments for rare hematologic and musculoskeletal disorders, went public in April.  With the IPO quiet period expiring, analysts are starting coverage of the stock — and adopting a bullish...